ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate

Stock News

Yesterday

ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.

The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1108389066"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108389066\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108389066?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 16:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108389066","market":"sh","top_or_hot":-1,"title":"ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate","media":"Stock News","content":"<p><b>ST Renfu (600079.SH)</b> announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.<br><br>The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST Renfu Initiation of Phase II Clinical Study for Novel Postoperative Pain Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-03 16:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>ST Renfu (600079.SH)</b> announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.<br><br>The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"","article_id":"1108389066","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108389066","pubTimestamp":1788423398,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600079":"ST人福","BK0012":"证金概念","IBBQ":"Invesco Nasdaq Biotechnology ETF","PSYK":"PSYK ETF","BMED":"iShares Health Innovation Active ETF","BK0028":"国家队","BK0185":"二线龙头","BK0239":"医药制造","MDTX":"Corgi MediaTek 2x Daily ETF","BK0096":"民营医院","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0070":"员工持股","BK0188":"融资融券"},"translate_title":"ST人福启动新型术后疼痛候选药物II期临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600079":1,"IBBQ":1,"IBBJ":1,"MDTX":1,"BMED":1,"PSYK":1},"content_text":"ST Renfu (600079.SH) announced that its controlled subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (in which the company holds an 80% stake), has commenced a Phase II clinical trial for its investigational drug RFUS-949 tablets.The multi-center, randomized, double-blind, parallel-group, placebo-controlled study is designed to evaluate the efficacy and safety of RFUS-949 tablets in managing pain following abdominal surgery. The trial aims to assess the drug's therapeutic potential for postoperative analgesia and to explore appropriate dosage regimens for this indication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}